CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
The 77th American Academy of Neurology Congress, held in San Diego, USA, on 5-9 April 2025, was attended in person or online by 14,500 neurology specialists from 110 countries.
Growing experience of dual anti-CGRP therapy, presented at AAN2025, is reinforcing its efficacy and safety in preventing and controlling migraine. Further results from the Phase 4 TANDEM open label study of atogepant 60 mg QD for migraine prevention and ubrogepant 100 mg PRN to treat breakthrough migraine attacks, together with real world experience of combined …
Read more »Consistent improvements in pain and ability to function, with high levels of patient satisfaction have been reported in the prospective, real-world observational CONFIDENCE study of adults using rimegepant to treat migraine attacks. Eligible participants had 3-14 headache days within the previous 30 days and planned to treat some future attacks with rimegepant. Using the Migraine …
Read more »Anti-CGRP therapies may play a useful role in preventing headaches triggered by the weather or by fasting.1,2 A post-hoc analysis of results from the Phase 3 HALO-EM trial of fremanezumab in adults with episodic migraine (EM) used daily headache diary data from US enrolled participants and daily, region-specific weather variables (pressure, temperature, relative humidity, precipitation, …
Read more »A third of patients switching to fremanezumab from other CGRP mAbs achieved a mean monthly migraine day (MMD) reduction of ≥50% within six months in the real world, non-interventional FINESSE study in adults with episodic and chronic migraine. Clinically meaningful reductions in MMD, migraine and headache-related disability, and acute medication use occurred during the full …
Read more »Results of two systematic reviews and meta analyses each with approximately 3000 patients with migraine and medication overuse headache (MOH), highlight the efficacy of anti-CGRP therapies in reducing monthly migraine and headache days, and improving daily life.1,2 In the first analysis of 10 randomised controlled trials (RCTs) with 3925 patients, 2786 (70.98%) received CGRP mAbs, …
Read more »Cycling through two or more triptans in search of migraine control may increase use of other therapies, increase the risk of medication overuse headache, and result in more ER visits, diagnostic imaging and outpatients, leading to higher costs. These are the conclusions of a retrospective claims analysis of MarketScan Databases (January 1, 2015-February 28, 2023) …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
